For example, concurrent to MSLT-II, landmark trials led to immune checkpoint blockade and BRAF/MEK inhibitors becoming the standard of care when adjuvant therapy was indicated for resected stage III melanoma in the setting of CLND [121,123,125]. This evidence concerns the gene MAP2K7 and melanoma.